Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

408 OXALIPLATIN
Vision blurred
(2004): Gowda A+, Oncology (Williston Park) 18(13), 1671
Vision loss
(2006): O’Dea D+, Clin J Oncol Nurs 10(2), 227
Other
Abdominal pain
(2005): Mis L+, Ann Pharmacother 39(5), 966
Anaphylactoid reactions/Anaphylaxis
(2007): Lee MY+, Support Care Cancer 15(1), 89
(2006): Sagawa T+, Gan To Kagaku Ryoho 33(13), 2093
(2006): Saif MW, Expert Opin Drug Saf 5(5), 687
(2005): Gonzalez-Mahave I+, J Investig Allergol Clin Immunol
15(1), 75
(2005): Maindrault-Goebel F+, Eur J Cancer 41(15), 2262
(2001): Alliot C+, ClinOncol(RCollRadiol)13(3), 236
(2001): Arotcarena R+, Gastroenterol Clin Biol 25(2), 206
(1999): Larzilliere I+, Am J Gastroenterol 94(11), 3387
(1999): Medioni J+, Ann Oncol 10(5), 610
(1998): Tournigand C+, Eur J Cancer 34(8), 1297
Chills
(2006): Saif MW, Expert Opin Drug 5(5), 687
(2005): Mis L+, Ann Pharmacother 39(5), 966
Cough (11%)
Death
Extravasation
(2003): Kretzschmar A+, J Clin Oncol 21(21), 4068
Fever (25%)
(2006): Saif MW, Expert Opin Drug 5(5), 687
(2004): Gowda A+, Oncology (Williston Park) 18(13), 1671
(2003): Thomas RR+, Cancer 97(9), 2301
(2000): Ulrich-Pur H+, Oncology 59(3), 187
Hepatotoxicity
(2006): Arotcarena R+, Gastroenterol Clin Biol 30(11), 1313
Hot flashes (2–5%)
Hypersensitivity
(2007): Edmondson DA+, Am J Ther 14(1), 116
(2006): de Vries RS+, Ann Oncol 17(11), 1723
(2006): Herrero T+, J Investig Allergol Clin Immunol 16(5), 327
(2006): Hewitt MR+, Clin Colorectal Cancer 6(2), 114
(2006): Saif MW, Expert Opin Drug Saf 5(5), 687 (12%)
(2006): Siu SW+, Ann Oncol 17(2), 259
(2005): Bonosky K+, Clin J Oncol Nurs 9(3), 325
(2005): Mis L+, Ann Pharmacother 39(5), 966
(2005): Ng CV, Ann Pharmacother 39(6), 1114 (2 cases)
(2004): Bhargava P+, Cancer 100(1), 211
(2004): Gowda A+, Oncology (Williston Park) 18(13), 1671
(19%)
(2004): Lim KH+, Anticancer Drugs 15(6), 605
(2003): Brandi G+, Br J Cancer 89(3), 477 (13%)
(2003): Lenz G+, Anticancer Drugs 14(9), 731
(2003): Thomas RR+, Cancer 97(9), 2301
(2002): Meyer L+, J Clin Oncol 20(4), 1146
(2002): Wilson RH+, J Clin Oncol 20(7), 1767 (to cold)
Injection-site edema
Injection-site erythema
Injection-site extravasation
Injection-site necrosis
Injection-site pain
(2002): Wilson RH+, J Clin Oncol 20(7), 1767
Injection-site reactions (sic)
(2003): Fracasso PM+, Gynecol Oncol 90(1), 177 (3 cases)
Myalgia/Myositis/Myopathy/Myotoxicity (2–5%)
Neurotoxicity (48%)
(2006): Arotcarena R+, Gastroenterol Clin Biol 30(11), 1313
(2006): Fracasso PM+, Gynecol Oncol 103(2), 523
(2006): Kiernan MC+, Curr Med Chem 13(24), 2901
(2006): Mitchell PL+, Clin Colorectal Cancer 6(2), 146
(2006): Pasetto LM+, Crit Rev Oncol Hematol 59(2), 159
(2006): Pietrangeli A+, Eur Neurol 56(1), 13
(2006): Shirao K+, Jpn J Clin Oncol 36(5), 295
(2006): Susman E, Lancet Oncol 7(4), 288
(2005): Cersosimo RJ, Ann Pharmacother 39(1), 128
(2004): Leonard GD+, Anticancer Drugs 15(7), 733
Pain (14%)
(2003): Mancuso A+, Anticancer Res 23(2C), 1917
Upper respiratory infection (7%)
(2005): Mis L+, Ann Pharmacother 39(5), 966
OXAPROZIN
Trade names: Daypro (Pfizer); Deflam; Duraprox
Indications: Arthritis
Category: Non-steroidal anti-inflammatory
Half-life: 42–50 hours
Clinically important, potentially hazardous interactions
with: methotrexate
Reactions
Skin
Angioedema (